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Kinase Inhibition for Treatment 
of Cancer
Uncontrolled proliferation of tumor 
cells is a hallmark of cancer. In many 
types of cancer, mutations in genes that 
activate cellular signal transduction 
pathways contribute to enhanced 
proliferation and survival of cancer 
cells. One well-characterized example 
is mutation in tyrosine kinases, enzymes 
that regulate the growth and survival 
of cells. Tyrosine kinase activity is 
tightly regulated in normal cells, but 
is dysregulated due to mutation in 
some cancers, including lung cancer, 
resulting in enhanced proliferation and 
survival of cancer cells. The tyrosine 
kinases are attractive candidates for 
molecularly targeted therapy in cancer, 
because cancers become dependent 
on growth signals from the mutant 
tyrosine kinases. Tyrosine kinases 
require ATP for their enzymic activity, 
and thus small molecules that mimic 
ATP can bind to mutant kinases and 
inactivate them.
The paradigm for tyrosine kinase 
inhibition as treatment for cancer 
using small-molecule inhibitors was 
ﬁ  rst established in the context of 
chronic myelogenous leukemia (CML) 
associated with the BCR-ABL gene 
rearrangement [1]. Imatinib (Gleevec), 
a 2-phenylaminopyrimidine, is a 
competitive inhibitor of ATP binding 
to the ABL kinase, thereby inhibiting 
the constitutively activated BCR-ABL 
tyrosine kinase. Imatinib induces 
complete remission in most patients 
with CML in stable phase [1], and also 
has activity in CML that has progressed 
to blast crisis [2]. 
Imatinib is also a potent inhibitor of 
the ARG, KIT, PDGFRA, and PDGFRB 
tyrosine kinases. As a consequence, 
there have been additional dividends 
from the United States Federal Drug 
Administration approval of imatinib for 
treatment of BCR-ABL-positive CML. 
For example, imatinib is effective in 
treatment of chronic myelomonocytic 
leukemia with gene rearrangements 
that constitutively activate PDGFRB 
[3], of hypereosinophilic syndrome 
with activating mutations in PDGFRA 
[4], and of gastrointestinal stromal 
cell tumors associated with activating 
mutations in KIT [5] (all reviewed in 
[6]). 
More recently, this paradigm has 
been extended to treatment of non-
small cell lung cancer (NSCLC). 
Several mutations have been identiﬁ  ed 
in the context of epidermal growth 
factor receptor (EGFR) in patients with 
NSCLC that are associated with clinical 
response to the small-molecule EGFR 
inhibitors geﬁ  tinib (Iressa) or erlotinib 
(Tarceva) [7,8,9], including in-frame 
deletions such as del L747–E749;A750P 
in exon 19, or L858R in exon 21. 
Although responses are often dramatic, 
most responding patients ultimately 
develop clinical resistance and relapse 
of disease [7,8,9]. The basis for 
resistance had not been known, in part 
owing to the difﬁ  culty in obtaining 
tissue from re-biopsy at time of relapse. 
Resistance to Small-Molecule 
Tyrosine Kinase Inhibitors
As might have been anticipated in 
treatment of cancer with any single 
agent, resistance to small-molecule 
tyrosine kinase inhibitors has emerged 
as a signiﬁ  cant clinical problem. This 
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Figure 1. Erlotinib Bound to the EGFR Kinase 
Domain 
Schematic representation of the wild-type 
EGFR tyrosine kinase domain (cyan) 
bound to erlotinib (orange) from the 
Protein Data Bank (http:⁄⁄www.rcsb.
org/pdb/) entry 1M17. The threonine 
790 side chain is shown in green. The 
positions of the phosphate-binding 
loop (P-loop), the αC-helix, and the 
activation loop (conserved structural 
features in kinase domains) are shown for 
reference. Sites of common lung-cancer-
associated drug-sensitive mutations (exon 
19 deletion [del] and L858R) are also 
depicted. 
(Figure: Nikola Pavletich, Structural 
Biology Program, Memorial Sloan-
Kettering Cancer Center)PLoS Medicine  |  www.plosmedicine.org 0196
was ﬁ  rst appreciated in patients with 
CML treated with imatinib whose 
tumors developed resistance, and has 
been most extensively studied in that 
context. Although there are many 
potential mechanisms for development 
of clinical resistance, most cases of 
imatinib-resistant CML are due to 
point mutations in the BCR-ABL kinase 
domain itself, including T315I [10,11]. 
Similar mutations in the homologous 
residues of the kinase domains of 
PDGFRA (T674I) and KIT (T670I) 
account for imatinib resistance in 
some patients with hypereosinophilic 
syndrome and  gastrointestinal stromal 
cell tumors, respectively [4,12]. These 
ﬁ  ndings suggest strategies to overcome 
resistance that include the use of 
alternative small-molecule inhibitors. 
Indeed, about three years after the 
recognition of imatinib resistance 
mutations in BCR-ABL-positive CML, 
new drugs are now in clinical trials 
that are potent inhibitors of imatinib-
resistant BCR-ABL mutants [13,14].
A Basis for Resistance to Small-
Molecule EGFR Inhibitors in NSCLC
In an elegant new study in PLoS 
Medicine, Pao and colleagues have 
identiﬁ  ed acquired mutations in 
patients with NSCLC that appear 
to explain clinical resistance to 
geﬁ  tinib or erlotinib [15]. The 
mechanism of resistance in three 
patients was acquisition of a T790M 
substitution in EGFR that was not 
present at time of diagnosis, but was 
detected with progression of disease 
after initial response to geﬁ  tinib or 
erlotinib. T790M in the context of 
either transiently expressed wild-
type EGFR or the mutant alleles del 
L474–E749;A750P or L858R impairs 
inhibition by geﬁ  tinib or erlotinib 
as assessed by autophosphorylation. 
Furthermore, the NSCLC cell line 
H1975 harbors both the L858R and 
T790M mutations, and is resistant to 
inhibition by geﬁ  tinib or erlotinib, 
unlike cell lines that express the L858R 
allele alone. In the H1975 cell line, 
it was possible to obtain adequate 
quantities of RNA to conﬁ  rm that 
the L858R and T790M mutations are 
present on the same allele, as would be 
predicted if T790M confers resistance 
to inhibition of the L858R allele. 
Structural models of EGFR provide 
structural insights into these biological 
data. A ribbon structure of erlotinib 
bound to the EGFR kinase domain 
(Figure 1) shows the threonine residue 
at position 790 in green and the 
positions of the exon 19 and L858R 
gain-of-function mutations. Substitution 
of methionine for threonine at position 
790 would be predicted to result in 
steric hindrance of erlotinib binding to 
EGFR (Figure 2).
These observations provide 
convincing evidence that, at least in 
some patients with NSCLC, resistance 
to geﬁ  tinib or erlotinib can be 
attributed to acquisition of a T790M 
mutation in the context of EGFR. 
However, three additional patients 
with clinical resistance to geﬁ  tinib 
or erlotinib did not have the T790M 
mutation, nor did they have mutant 
KRAS alleles that have previously been 
shown by these same authors to confer 
resistance to these inhibitors [9]. 
Thus, mechanisms of resistance are 
heterogeneous.
Next Steps, and Lessons Learned
It will be important to identify 
alternative small-molecule inhibitors 
for the T790M resistance mutation. 
Structural data suggest that one 
compound, lapatinib, may subserve 
this purpose [16], but it has not been 
tested for biological activity in this 
context. New chemical screens and/
or rational drug design to identify 
alternative inhibitors is warranted. In 
addition, only half of this small cohort 
of patients with NSCLC with clinical 
resistance to geﬁ  tinib or erlotinib had 
the T790M substitution. Efforts to 
identify alternative mechanisms for 
resistance may be guided by experience 
with imatinib resistance in the context 
of BCR-ABL, and should include full-
length sequencing of EGFR to identify 
other resistance mutations, and analysis 
for evidence of gene ampliﬁ  cation, 
as well as investigation of other well-
characterized mechanisms of drug 
resistance such as drug efﬂ  ux or 
increased drug metabolism. 
Pao and colleagues’ superb study 
also highlights several important points 
that may guide development of kinase-
targeted therapies in the future. It is 
clear that, to the extent that small-
molecule kinase inhibitors are effective 
as single agents in treatment of cancer, 
resistance will develop. Furthermore, 
based on previous experience, some 
of these patients are likely to harbor 
acquired point mutations in the 
target kinase that confer resistance. 
Resistance mutations identiﬁ  ed via 
in vitro screens have shown a high 
degree of correlation with those that 
develop in vivo, as shown in screens for 
imatinib-resistant BCR-ABL mutants 
[11] and PKC412-resistant FLT3 
mutants [17], as well as the T790M 
resistance mutation to geﬁ  tinib in 
the context of EGFR [18]. Thus, 
in vitro screens for mutations that 
confer resistance to kinase inhibitors 
are warranted, followed by efforts to 
identify drugs that overcome resistance. 
This proactive approach should 
shorten the time frame for new drug 
development. 
DOI: 10.1371/journal.pmed.0020075.g002
Figure 2. Structural Models of EGFR Showing 
the T790M Resistance Mutation 
(A) Space-ﬁ  lling representation of the 
wild-type kinase active site (cyan) with the 
viewer looking down the vertical axis. The 
structure above the plane of the ﬁ  gure 
is omitted for clarity. The threonine 
790 side chain is green, and erlotinib’s 
molecular surface is shown as a yellow 
net. 
(B) The threonine 790 side chain 
is replaced by the corresponding 
methionine side chain from the structure 
of the insulin receptor tyrosine kinase 
(Protein Data Bank entry 1IRK). The 
EGFR and insulin receptor have a similar 
structure in this region of the active 
site. The methionine side chain would 
sterically clash with erlotinib, as shown, as 
well as with the related kinase inhibitor 
geﬁ  tinib (not shown). 
(Figure: Nikola Pavletich, Structural 
Biology Program, Memorial Sloan-
Kettering Cancer Center)
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These ﬁ  ndings also emphasize the 
critical need for re-biopsy of patients 
with cancer treated with molecularly 
targeted therapies at time of relapse. 
Tissue acquisition is more challenging 
in solid tumors than for hematopoietic 
malignancies, and may entail risk. 
Nonetheless, it is clear that data derived 
from such analyses will be essential 
to inform approaches to improving 
therapy for NSCLC and other solid 
tumors.  
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